Measurement of lupus activity and cumulative damage in patients with systemic lupus erythematosus
Keywords:
systemic lupus erythematosus, disease activity, damage, MEX-SLEDAI, validationAbstract
Introduction: measuring the activity of the disease and the irreversible damage in patients with systemic lupus erythematosus is of vital importance to evaluate the outcome measures of the patient and their prognosis, the differences between groups of patients and the responses to new treatments.
Objective: to determine the degree of lupus activity and accumulated damage in a group of patients with systemic lupus erythematosus.
Method: an observational, descriptive, cross-sectional study was conducted at the "Mártires del 9 de Abril" University Hospital in Sagua la Grande, Villa Clara province, in the period from January 2013 to September 2018. The sample, selected in a non-probabilistic manner by criteria, was composed of 53 patients with a diagnosis of systemic lupus erythematosus.
Results: the mean score of the MEX-SLEDAI scale was 5.8 ± 3.7 points (range 1-17 points). 37.7 % of the patients presented mild activity, only 1.9 % presented very severe activity and 17 % were in remission or without activity. The most affected areas of the SLICC / ACR index were musculoskeletal (17.0 %), cardiovascular (17.0 %) and cutaneous (15.1 %).
Conclusions: the patients studied showed a predominance of mild to moderate disease activity according to MEX-SLEDAI. The presence of cardiovascular damage was higher than that reported by other studies. A significant correlation was found between the presence of lupus activity and accumulated damage.
Downloads
References
Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev [Internet]. 2014 [citado Oct 26 2018];13(11):1082-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25172239
Dubuc CAE, Ecenarro MU, Villalba CM, Cáceres VA, Rubio IH, Otano JB. Síndrome hemofagocítico como manifestación clínica inicial del lupus eritematoso sistémico. Reumatología Clínica [Internet]. 2014 [citado Oct 26 2018]; 10(5):321-4. Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X13002052
Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. En: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, editores. Kelley's Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2013. p. 79-85.
Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, Galindo-Izquierdo M, Loza E, García de Yebenes MJ, et al. Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. Reumatol Clin [Internet]. 2014 [citado Oct 26 2018];10(1):17-24. Disponible en: http://www.reumatologiaclinica.org/es/registro-nacional-pacientes-con-lupus/articulo/S1699258X13001071/
Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev [Internet]. 2014 [citado Oct 26 2018];13(11):1082-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25172239
Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878-88.
García-Carrasco M, Mendoza-Pinto C, Ayón-Aguilar J, Soto-Santillán P, Rodríguez-Gallegos A, Escamilla-Márquez MA, et al. Niveles séricos de vitamina D en pacientes con lupus eritematoso sistémico (LES) y su asociación con la actividad de la enfermedad: estudio longitudinal. Gac Med Mex [Internet]. 2016 [citado Oct 26 2018]; 152:32-7. Disponible en: http://www.medigraphic.com/pdfs/gaceta/gm-2016/gms162d.pdf
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum [Internet]. 1992 [citado Oct 26 2018]; 35(6):630-40. Disponible en: https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.1780350606
Chang E, Abrahamowicz M, Ferland D, Fortin PR. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol [Internet]. 2002 [citado Oct 26 2018]; 55(5):488-97. Disponible en: https://www.jclinepi.com/article/S0895-4356(01)00509-1/abstract
Castrejón I, Rúa-Figueroa I, Rosario MP, Carmona L. Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. Reumatol Clin [Internet]. 2014 [citado Oct 26 2018]; 10(5):309-20. Disponible en: http://www.reumatologiaclinica.org/en/clinical-composite-measures-disease-activity/articulo/S2173574314001245/
Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol [Internet]. 1992 [citado Oct 26 2018];19:1551-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/1464867
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol. 1992;19:1820-1.
development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum [Internet]. 1996 [citado Oct 26 2018]; 39:363–9. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/art.1780390303/full
Pinto-Peñaranda LF, Echeverri-García AF, Velásquez-Franco CJ, Mesa Navas MA, Muñoz-Grajales C, Zuluaga-Quintero M, et al. Daño de órgano en una cohorte de pacientes colombianos con lupus eritematoso sistémico: caracterización y factores asociados. Rev Colomb Reumatol [Internet]. 2018 [citado Oct 26 2018]; 25(2): 85-91. Disponible en: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-dano-organo-una-cohorte-pacientes-S0121812318300343?referer=buscador
Rahman P, Gladman D, Urowitz M, Hallett D, Tam L. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10:93-6.
Guibert Toledano ZM. Actividad lúpica y daño acumulado en una cohorte de pacientes cubanos con lupus eritematoso sistémico (LES) [tesis]. La Habana: Hospital Clínico Quirúrgico 10 de Octubre; 2009 [Internet]. [citado Oct 26 2018]. Disponible en: http://tesis.repo.sld.cu/126/1/Zoila_Marlene_Guibertoledano.pdf
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum [Internet]. 2012 [citado Oct 26 2018];64:2677-86. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/art.34473
Rivas-Larrauri F, Yamazaki-Nakashimada MA. Lupus eritematoso sistémico: ¿es una sola enfermedad?. Reumatol Clin [Internet]. 2016 [citado Oct 26 2018];12(5):274–281. Disponible en: https://www.sciencedirect.com/science/article/pii/S1699258X16000103
AG Vilá LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcón GS. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004; 31(10):1934-40.
Ayala Saucedo AR, Torres de Taboada E, Montiel de Jarolín D. Causas de fiebre en pacientes adultos con lupus eritematoso sistémico. Rev. virtual Soc. Parag. Med. Int [Internet]. 2017 [citado Oct 26 2018]; 4(1):35-45. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=5872979
Medina JE, Mora C, Jaimes DA, Arbeláez AM, Valencia PA, Salazar RE, et al. Valoración de la actividad, del daño crónico y alteración de la calidad de vida en una cohorte de pacientes colombianos con lupus eritematoso sistémico por medio de SELENA-SLEDAI, BILAG 2004, SLICC/ACR y SF-36. Rev Colomb Reumatol [Internet]. 2013 [citado Oct 26 2018]; 20(4):211-217. Disponible en: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-articulo-valoracion-actividad-del-dano-cronico-S012181231370135X?referer=buscador
Barahona-López DM, Sánchez-Sierra LE, Matute-Martínez CF, Barahona-López IA Perdomo-Vaquero R, Erazo-Trimarchi G. Hospitalización en lupus eritematoso sistémico: causas, actividad lúpica y evolución. Med Int Méx [Internet]. 2017 [citado Oct 26 2018]; 33(6):730-738. Disponible en: http://www.medigraphic.com/pdfs/medintmex/mim-2017/mim176d.pdf
Guibert Toledano ZM, Reyes Llerena Gil A, Hernández Martínez A, Torres Carballeira R. Medición de actividad Lupica en pacientes portadores de Lupus Eritematoso Sistémico (LES). Rev Cubana Reumatol [Internet]. 2000 [citado Oct 26 2018]; 2(1):4-11. Disponible en: https://dialnet.unirioja.es/descarga/articulo/4940588.pdf
Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid and renal and
pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:248–54.
Olsen NJ, Yousif M, Mutwally A, Cory M, Elmagboul N, Karp D. Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int 2013; 33:2585-90.
Estévez del Toro M, Chico Capote A, Echavarría R, Jiménez Paneque R, Kokuina E. Daño en pacientes cubanos con lupus eritematoso sistémico. Relación con características de la enfermedad. Reumatol Clin [Internet]. 2010 [citado Oct 26 2018]; 6(1):11-15. Disponible en: http://www.reumatologiaclinica.org/es/pdf/S1699258X09001569/S300/
Alarcón GS, McGwin Jr G, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in the three ethnic groups: VII. Predictors of early mortality in the LUMINA cohort. Arthritis Care Res. 2001;45:191-202.
Rivest C, Lew RA, Welsing PM, Sangha O, Wright EA, Roberts WN, et al. Association between clinical factors, socioeconomic status and organ damage in recent onset systemic lupus erythematosus. J Rheumatol. 2000;27:680-4.
Guibert Toledano Z. M., Reyes Llerena Gil A., López Cabreja G.González Otero Z A., Lic. Betancourt Herrera L. Indice de daño en el Lupus E. Sistémico (SLICC/ACR). Su análisis en pacientes cubanos; 1997- 998. Rev. Cubana de Reumatología. 2000; 2 (1):45-48.
Rodríguez Hernández R, Alberteris Rodríguez A, López Báster J, Diéguez Martínez M, Miguel-Soca PE, Cutié Anido Y. Factores de riesgo asociados a hipertensión arterial en pacientes con lupus eritematoso sistémico. Holguín, Cuba. Rev haban cienc méd [revista en Internet]. 2017 [citado Oct 26 2018]; 16(6):[aprox. 7 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/1978
Guibert Toledano ZM, Reyes Llerena GA, Hernández Muñiz Y, Ugarte Moreno D, Miñoso Arafi Y. Morbilidad cardiovascular y evaluación de aterosclerosis en pacientes con lupus eritematoso sistémico. Rev Cubana de Reumatolo [Internet]. 2016 [citado Oct 26 2018];18(2):[aprox. 8 p.]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/494
Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology [Internet]. 2012 [citado Oct 26 2018]; 51(3): 491-498. Disponible en: https://pdfs.semanticscholar.org/0f45/39b69f9dbd420d4fec2b3172513f566360ad.pdf
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
